key: cord-0261214-839k9a9e authors: Betka, S. J. A.; Kannape, O. A.; Fasola, J.; Lance, F.; Cardin, S.; Schmid, A.; Similowski, T.; Soccal, M. P.; Herbelin, B.; Adler, D.; Blanke, O. title: Virtual reality exercise to help COVID patients with refractory breathlessness date: 2021-10-26 journal: nan DOI: 10.1101/2021.10.26.21265510 sha: 12432c006bdd3c9f925523f7e84c69d403eeb313 doc_id: 261214 cord_uid: 839k9a9e Background: Immersive virtual reality (iVR)-based digital therapeutics (DTx) are gaining clinical attention in the field of pain management. Based on known analogy between chronic pain and dyspnea, we investigated the effects of visual respiratory feedback in iVR, on refractory breathlessness in patients recovering from severe COVID-19 pneumonia. Methods: We performed a controlled, randomized, single-blind, cross-over clinical study to evaluate an iVR-based intervention to alleviate refractory breathlessness in patients recovering from COVID-19 pneumonia. The single-site study was conducted at the university hospital of Geneva, Switzerland. Patients reported refractory breathlessness ([≥]5 on a 10-point dyspnea scale) and had a MoCA score of [≥]24. Cross-over groups were randomly assigned, concealed from the referring clinician. Participants received synchronous (intervention) or asynchronous (control) feedback of their breathing, embodied via a gender-matched avatar in iVR. Prior to the first exposure and following both experimental conditions, patients completed questionnaires. Breathing patterns were captured continuously. The COVVR clinical study is registered with ClinicalTrials.gov (NCT04844567) and is now closed. Findings: Study enrollment was open between November 2020 and April 2021. A total of 26 patients (27% women; age: mean=57, SD{+/-}12) were enrolled; 14 patients were randomly assigned to the ''synchronous/asynchronous'' sequence, 12 to the ''asynchronous/synchronous'' sequence. Data was available for all except two (7.7%) of 26 patients. The mean rating of breathing comfort was 0.1 at baseline, 0.8{+/-}1.8 for asynchronous, and 1.3{+/-}1.4 synchronous feedback (estimated difference of 0.5 (95%CI 0.05 to 1.04; p<0.05) between iVR conditions). Of all patients, 91.2% were satisfied with the intervention (1.8{+/-}1.6, t=5.201, p<0.0001, 95%CI 1.173 to inf) and 66.7% perceived it as beneficial for their breathing (0.7{+/-}1.9, t=1.806, p<0.05, 95%CI 0.036 to inf). No adverse events were reported. Interpretation: Based on these findings, we propose that our iVR-based DTx is a feasible and safe neuro-rehabilitation tool that improves breathing comfort in patients recovering from severe COVID-19 infection. More research is needed to generalize this tool in other groups of patients suffering from refractory breathlessness. Background Immersive virtual reality (iVR)-based digital therapeutics (DTx) are gaining clinical attention in the field of pain management. Based on known analogy between chronic pain and dyspnea, we investigated the effects of visual respiratory feedback in iVR, on refractory breathlessness in patients recovering from severe COVID-19 pneumonia. We performed a controlled, randomized, single-blind, cross-over clinical study to evaluate an iVR-based intervention to alleviate refractory breathlessness in patients recovering from COVID-19 pneumonia. The single-site study was conducted at the university hospital of Geneva, Switzerland. Patients reported refractory breathlessness (≥5 on a 10-point dyspnea scale) and had a MoCA score of ≥24. Cross-over groups were randomly assigned, concealed from the referring clinician. Participants received synchronous (intervention) or asynchronous (control) feedback of their breathing, embodied via a gender-matched avatar in iVR. Prior to the first exposure and following both experimental conditions, patients completed questionnaires. Breathing patterns were captured continuously. The COVVR clinical study is registered with ClinicalTrials.gov (NCT04844567) and is now closed. Study enrollment was open between November 2020 and April 2021. A total of 26 patients (27% women; age: mean=57, SD±12) were enrolled; 14 patients were randomly assigned to the "synchronous/asynchronous" sequence, 12 to the "asynchronous/synchronous" sequence. Data was available for all except two (7.7%) of 26 patients. The mean rating of breathing comfort was 0.1 at baseline, 0.8±1.8 for asynchronous, and 1.3±1.4 synchronous feedback (estimated difference of 0.5 (95%CI 0.05 to 1.04; p<0.05) between iVR conditions). Of all patients, 91.2% were satisfied with the intervention (1.8±1.6, t=5.201, p<0.0001, 95%CI 1.173 to inf) and 66.7% perceived it as beneficial for their breathing (0.7±1.9, t=1.806, p<0.05, 95%CI 0.036 to inf). No adverse events were reported. Chronic breathlessness syndrome has recently been delineated as a disabling sensation of difficult breathing despite optimized treatment of underlying medical conditions 1 . Although chronic breathlessness, as a syndrome, has originally been described in chronic medical conditions, refractory breathlessness (RB) despite optimized treatment, can also be observed in acute settings 2 . The condition has a non-negligible deleterious impact on patients' quality of life and autonomy, by impacting cognition, locomotion, or mental health 3, 4 . RB's definition emphasizes the importance of a complete work-up and identification of the underlying condition for the appropriate pathophysiological treatment; it also underlines the current failure to study an under-recognized respiratory suffering 1,2 and the need for development of evidenced-based interventions for RB. Indeed, breathlessness remains under-recognized in the hospital setting, although it can be easily collected and rated by trained staff and is associated with short and longer-term mortality 5 . Neuroimaging evidence suggests that the perception of breathlessness is underpinned by a neural network involving the insula, dorsal anterior cingulate cortex, amygdala, and medial thalamus and shares important pathways with other brain functions such as pain processing 6 and bodily self-consciousness 8 . Prior interventions using immersive virtual reality (iVR)-based Digital Therapeutics (DTx), also referred to as digiceuticals 9 , have demonstrated alleviation of chronic pain in patients with complex regional pain syndrome or spinal cord injury 10, 11 . In the respiratory domain, visuorespiratory stimulation (based on visuo-respiratory feedback) has been associated with an increased feeling of breathing control (breathing agency) 12 , a reduced negative emotional state related to experimental dyspnea 13 , as well as changes in physiological measures of breathing 7, 14 . Long COVID is a complex condition with multiples symptoms occurring beyond the initial period of COVID-19 infection recovery and affects patients who were managed in the community or in the acute care setting 8 . Like general weakness, malaise, fatigue, and concentration impairments, breathlessness has consistently been reported in long COVID cohorts with a high prevalence of around 25% (CI95 18% to 34%) 7 . As the subjective experience of breathlessness is poorly associated to specific physiological markers such as pulmonary function tests or lung imaging in long COVID 8 , treatment is challenging and is most often focused on pulmonary rehabilitation 17 . This also implies that a cognitive intervention 1 A controlled, randomized, single-blind, cross-over clinical study was conducted to evaluate both efficacy and feasibility of a Virtual Reality biofeedback intervention to alleviate RB in patients recovering from severe COVID-19 pneumonia. This single-site study was carried out at the University Hospital (HUG) in Geneva, Switzerland and was approved by the Commission Cantonale d'Ethique de la Recherche de la République et Canton de Genève (2019-02360). Thirty-one patients were recruited for the study (see Figure 1 ). Clinical inclusion criteria were that patients i) were recovering from severe COVID-19 pneumonia, and ii) presented with RB with a self-rated intensity of five or higher (out of ten) on a visual analogic dyspnea scale. Furthermore, patients had to be able to give consent and to understand and speak French or English. Patients that presented with unstable respiratory, neurological, or cardiac conditions, or psychiatric illness were excluded. Patients that scored below 25 on the Montreal Cognitive Assessment (MoCA) were also excluded. As the study employed a crossover design, patients were allocated to one of two starting conditions (synchronous, asynchronous) using a randomization script, prior to data collection. Randomization was not restricted; no stratification or minimization factors were applied. Allocation was concealed to the clinicians screening patients. Participant masking (blinding) was achieved by keeping both the procedure and the virtual environment identical for both tested conditions. Participants were naïve to the difference in the two conditions which consisted only of a change in feedback synchrony between respiratory movements and avatar luminance. Experimenters were not blinded, as they set up the VR device. However, the instructions were only given to the patient once before wearing the HMD and starting the intervention and applied to both conditions. All rights reserved. No reuse allowed without permission. Patients were screened by a respiratory physician during morning rounds. Individuals were referred to the study. It was then verified that the patients met the inclusion criteria by performing an anamnestic interview as well as the MoCA cognitive assessment. In the VR environment, patients could look around and see, next to them, a gender-matching virtual body lying on a bed in a similar position as theirs ( Figure 2 ). The virtual body was flashing in a waxing and waning visual effect. This visual effect could be in synchrony (synchronous condition) or in massive asynchrony (asynchronous condition) with the patient's respiratory movements. In the synchronous condition, the radiance of the visual flash was maximal at the end of inspiration and minimal at the end of the expiration. In the asynchronous condition, at the end of each visual flash a duration between 2.5 and 33.3 seconds is randomly generated for the next visual stimulation, such that the feedback is both phase-shifted and frequency-modulated with respect to the actual respiration. Once the patient was installed, a baseline assessment was performed, where patients closed their eyes (no visual feedback, NVF) and their respiratory movements recorded for two minutes. All rights reserved. No reuse allowed without permission. Participants were then asked to rate their current breathing comfort by answering two questions according to a 7-point Likert scale (from -3= Strongly disagree to +3= Strongly agree): 1) I have difficulty breathing and 2) My breathing is enjoyable. These two items were also included in the following questionnaires and used to evaluate changes in 1) breathing discomfort, and 2) breathing comfort. After baseline assessment, participants were randomly assigned in a 1:1 ratio to receive either the sequence "synchronous/asynchronous" or "asynchronous/synchronous". In each block, patients were asked to first look around in the VR room, and then to orient their gaze towards the virtual body while relaxing for 5 minutes. They were not informed that the flashing of the virtual body was related to their breathing. Each block was followed by a subjective questionnaire of six questions (7-point Likert scale) derived from previous visuo-respiratory studies 4-6 , (see Table 1 ). Question 1 evaluated the awareness of the visuo-respiratory experimental manipulation, while question 3 pertained to the breathing agency. Question 2 and 5 were proposed as control. Breathing comfort was evaluated with the same questions used in the baseline questionnaire (respectively Q4 and Q6, Table 1 ). Finally, to assess the acceptance and feasibility of the iVR intervention patients completed a feasibility questionnaire (7-point Likert scale, see supplementary section Table 4 ). Two primary outcomes were proposed. One, the efficacy of the intervention was evaluated based on subjective feedback by the patients regarding their breathing comfort and discomfort. With the 7-point Likert scale used, lower discomfort scores present a better outcome. Two, feasibility of the intervention was evaluated using a feedback questionnaire, alongside open feedback. Agreement with the questionnaire items indicates better feasibility, acceptance, and perceived outcome. Secondary outcome measures concerned respiratory parameters as well as the embodiment of the VR feedback. Both respiratory rate (RR, breaths per minute) and respiratory rate variability (RRV, using inter-breath intervals, IBI) were measured using the respiration belt. RR and RRV were compared across the baseline and two intervention conditions. Embodiment was evaluated using a 7-point Likert scale where agreement indicates stronger embodiment. Furthermore, two control questions were included. Based on previous work on breathing agency 13 , a necessary sample size of 21 patients was estimated, using a two-sided paired t-test with an effect size of 0.65, alpha of 0.05 and a power of 0.8 to demonstrate a difference of 0.5 between the two experimental conditions. The effect of synchrony on each measure was assessed using a linear mixed-effects model with a random intercept for each patient. In addition to the experimental condition (synchronous vs asynchronous condition), each model also included the experimental sequence (starting the experiment with synchronous or asynchronous condition) and the interaction between the experimental sequence and the experimental condition as fixed effects. The statistical significance of the interactions was assessed using the likelihood ratio test. All p-values were two-sided and statistical significance was set at a p-value of 0.05. Mean, standard deviation, and rating frequency (in%) were computed for each feasibility item. In order to ensure clarity, observed percentages for ratings from 1 = Agree to 3 = Strongly agree were grouped, indicating overall agreement with the statement. Finally, a one sided one-sample t-test was used to determine if the mean of ratings was significantly greater than zero, indicating that, at least, the majority of the patients were agreeing with the statement. As head-mounted displays are widely used in clinical and healthy populations no specific safety analysis was performed within the scope of this study. There is no evidence that using HMDs carry risks beyond those of CRT screens (e.g., with respect to binocular vision 18 or photosensitive epilepsy 19 ). As patients remained seated during the intervention there was no risk of falling or collisions. All analyses were performed using R (version 4.1.0) and Matlab (version 2020a). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All rights reserved. No reuse allowed without permission. From November 2020 to April 2021, patients' enrollment, randomization and testing took place at the division of Pneumology at Geneva University Hospital. Twenty-six patients were randomly assigned either to the "asynchronous/synchronous" sequence (n=12) or the "synchronous/asynchronous" sequence (n=14). At the time of database lock in May 2021, data was available for all except two (7.7 %) of 26 patients (Figure 1 ). 0.25 ± 1.6 (-2-2) 0.08 ± 1.6 (-3-2) Respiratory rate (bpm) 22 3.2 ± 2.1 (0.8-11.5) Table 2 Characteristics of the patients at randomisation in the intent to treat population. Data are presented as n (%) or mean±SD. SD: standard deviation. *Data were missing for some patients; the denominator in the asynchronous group was 10. Differences in subjective and physiological measures between conditions are reported in Table 2 . At baseline, the mean breathing comfort rating was 0.08 ±1.6 and the mean breathing discomfort rating was -0.04 ±1.8. Mean values and standard deviations for each experimental condition, in function of the experimental sequence are provided in supplementary Table 5 . Figure 3 .A). The order of conditions did not impact these findings (no significant interaction for comfort rating between experimental conditions (asynchronous or synchronous) and experimental sequence (starting the experiment with asynchronous stimulations or starting it with synchronous stimulations)). Moreover, post-hoc paired one-sided t-tests, confirmed a significant difference between breathing comfort ratings during the experimental (synchronous) condition compared to baseline. Such difference was absent for the control (asynchronous) condition, We also explored studies/randomized controlled trials (RCTs) of VR-based immersive DTx aimed at alleviating pain/refractory breathlessness. To maximize sensitivity, we also searched for citations in Google Scholar, Scopus, and Web of Science. Search terms included "COVID-19", "coronavirus", "breathlessness", "dyspnea", "virtual reality", "breathing", "respiration", "rehabilitation", "pain" and "immersive digiceuticals", either separately or in combination. In previous work in healthy populations, the manipulation of visuo-respiratory signals using VR was related to increased feeling of breathing control, reduced negative emotion during induceddyspnea and changes in physiological measures of breathing signal. Breathlessness is poorly associated to physiological impairment measured by pulmonary function tests or lung imaging in long COVID-19, which also implies that the brain could be a possible target for a neurorehabilitation. Alleviating breathlessness in Long COVID patients requires a clinically proven, easily adaptable, and inexpensive intervention. Previous iVR interventions manipulating visual cardiac feedback led to pain alleviation in clinical populations such as complex regional pain syndrome or spinal cord injury. In the respiratory domain, the manipulation of visuo-respiratory stimulations has been associated with reduced negative emotional state related to breathlessness, with changes in respiratory signals (rate, tidal volume variability and respiration amplitude), and with increased breathing agency (i.e. the feeling of sensing one's breathing command). In our COVVR controlled, randomized, single-blind crossover clinical study of 26 patients presenting with refractory breathlessness after COVID-19 infection, the effect of visuo-respiratory stimulations improved breathing comfort. Most patients were satisfied by the intervention and rated the iVR intervention as beneficial to improve this debilitating symptom. Given the scarcity of evidence-based treatment to treat refractory breathlessness, and the benefit of visuo-respiratory iVR-based intervention in patients recovering from COVID-19, we propose that our iVR-based immersive DTx is a safe and inexpensive neuro-rehabilitation tool that could be considered for use to increase breathing comfort in patients. Replication of our results in other clinical groups suffering from refractory breathlessness is recommended. In COVVR, an iVR-based immersive DTx improved breathing comfort in patients with RB recovering from severe COVID-19 pneumonia. During synchronous visuo-respiratory stimulation, breathing comfort significantly improved compared to the asynchronous control condition and to a baseline condition. A similar effect of the intervention was observed for breathing agency, i.e. the feeling of being in control of one's breathing. Finally, the vast majority of the sample reported a global satisfaction regarding the VR intervention and, more importantly, indicated that the iVR feedback improved their breathing. Our findings were neither modulated by the experimental sequence, nor can they be explained by VR distraction, or by changes in the respiratory measures during the intervention. RB, a common but underreported condition, is defined as breathlessness that persists despite optimal treatment of the underlying pathophysiology. This results in important disabilities impacting cognition, locomotion and mental health 3, 4, 20 . Mounting evidence using functional neuroimaging suggests that patients suffering from RB may exhibit brain "hypersensitivity" to afferent respiratory signals as a result of learned expectations during daily physical activities. 20 Perception and anticipation of breathlessness are known to share neural correlates such as brainstem areas or the insular cortex [21] [22] [23] . It is likely that our manipulation interacts with such systems. Consequently, once treatment of the underlying pathophysiology has been optimized, the brain may become a potential target for pharmacological and non-pharmacological interventions. Pharmacological treatments may also be useful; low dose oral sustained-release morphine administered for RB is associated with improved health status in COPD without affecting PaCO2 or causing serious side-effects, especially in patients with mMRC stage 3 to 4 20 . Pulmonary rehabilitation, an evidence-based multidisciplinary non-pharmacological intervention has also been shown to modify neural responses to learned breathlessness associations, which corresponds from a clinical point of view to central desensitization to dyspnea as an improvement in lung mechanics is most often not observed with this intervention 21 . Using iVR, the impact of visuo-respiratory stimulations on breathing has already been documented in healthy subjects, where the exposure to visuo-respiratory feedback led to increased breathing agency 12 , and to changes in respiratory rate 25 , tidal volume variability 14 , and respiration amplitude 26 . Moreover, a greater positive emotional state, during experimentally induced dyspnea (loaded breathing), has also been observed during a similar iVR intervention 13 . iVR DTx are becoming popular in the field of chronic pain management as standard therapies have many shortcomings such as the prescription of controversial opioid medication 25 . Of note, breathlessness and pain share striking similarities 6 . They engage similar brain networks 6 , are best characterized by multidimensional models 28 One important innovation this study demonstrates is the improved efficacy linked to real-time biofeedback, going beyond the classically admitted distraction from suffering offered by iVR 30 . Relying on the recent expansion of Internet of Things (IoT) technologies and of wearable physiological sensors in particular, our approach highlights how iVR DTx interventions can now more specifically target the neural mechanisms of pain and RB. Although in its current form our technology did not fulfill the expectations for home-use in our patients' cohort, it paves the way for future e-health products that would not only provide monitoring but also a continuum of interventions from hospital bed to patient's home. In conclusion, our study shows that an immersive VR-based digital therapeutic can improve breathing comfort in patients recovering from severe COVID-19 pneumonia. Global satisfaction and respiratory benefit from the patients are reported, attesting to the feasibility of this simple intervention. Although more clinical studies are needed, our iVR-based DTx may become a key factor of multi-dimensional treatment of refractory breathlessness. Every author named at the start of the article contributed to the study: Conceptualization (AD, BO All authors confirm that they had full access to all the data in the study and accept responsibility to submit for publication. FJ and BS verified the data. We declare no competing interests. Table 5 Means and standard deviations for the asynchronous and asynchronous conditions, in function of the experimental sequence. Breathing comfort -Tests against baseline Using post-hoc paired one-sided t-tests, we found a significant difference between breathing comfort ratings during the synchronous condition compared to baseline (Difference: 1.25±0.431, t = 2.901, p < 0.01, 95% CI 0.511 to inf). This was not observed between breathing comfort ratings during the asynchronous condition compared to baseline (Difference: 0.708±0.547, t = 1.296, p > 0.05, 95% CI -0.229 to inf), excluding a mere effect of VR distraction. Figure 6 Subjective measures for which the main effect of the experimental manipulation was not significant. The boxplots depicting subjects' ratings during asynchronous condition compared to the synchronous condition, independent of experimental sequence. The thick line within a box plot represents the median, the diamond represents the mean, the upper boundary of the box indicates the 25th percentile and lower boundary the 75th percentile. The whiskers above and below the box indicate the minimal and maximal values, while points above the upper or below the whiskers indicate outliers. Subjective ratings were measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree. Discomfort item:"I had difficulty breathing" Objective measures for which the main effect of the experimental manipulation was not significant. The boxplots depicting subjects' physiology signal during asynchronous condition compared to the synchronous condition, independent of experimental sequence. The thick line within a box plot represents the median, the diamond represents the mean, the upper boundary of the box indicates the 25th percentile and lower boundary the 75th percentile. The whiskers above and below the box indicate the minimal and maximal values, while points above the upper or below the whiskers indicate outliers. Subjective ratings were measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic Experimental dyspnoea interferes with locomotion and cognition: a randomised trial Psychosocial consequences of living with breathlessness due to advanced disease Association of dyspnoea, mortality and resource use in hospitalised patients Dyspnea and pain share emotion-related brain network Breathing control, brain, and bodily selfconsciousness: toward immersive digiceuticals to alleviate respiratory suffering Coupling Inner and Outer Body for Self-Consciousness Robotic Interfaces for the Conscious Mind Enhancing analgesic spinal cord stimulation for chronic pain with personalized immersive virtual reality Virtual reality improves embodiment and neuropathic pain caused by spinal cord injury Breathing and sense of self: visuorespiratory conflicts alter body self-consciousness Interferences between breathing, experimental dyspnoea and bodily selfconsciousness Mechanisms of the breathing contribution to bodily self-consciousness in healthy humans: Lessons from machine-assisted breathing? Characterising long term Covid-19: a living systematic review Dyspnoea, lung function and CT findings three months after hospital admission for COVID-19 COVID-19: Interim Guidance on Rehabilitation in the Hospital and Post-Hospital Phase from a European Respiratory Society and American Thoracic Societycoordinated International Task Force The visual effects of head-mounted display (HMD) are not distinguishable from those of desk-top computer display Concern of Photosensitive Seizures Evoked by 3D Video Displays or Virtual Reality Headsets in Children: Current Perspective All rights reserved. No reuse allowed without permission Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial Breathlessness and the brain: the role of expectation Expectation and dyspnea: The neurobiological basis of respiratory nocebo effects Interoception of breathing and its relationship with anxiety Treating breathlessness via the brain: changes in brain activity over a course of pulmonary rehabilitation Respiration Entrainment in Virtual Reality by Using a Breathing Avatar The 'embreathment' illusion highlights the role of breathing in corporeal awareness Virtual reality approaches to pain: toward a state of the science The multiple dimensions of dyspnea: review and hypotheses NICE guideline on long COVID Virtual reality for management of pain in hospitalized patients: A randomized comparative effectiveness trial All rights reserved. No reuse allowed without permission We thank Dr Elise Dupuis-Lozeron and Dr Fosco Bernasconi for their statistical advice.All rights reserved. No reuse allowed without permission.